About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

D.Western Therapeutics Institute, Inc.(4576) Summary

4576
TSE Growth
D.Western Therapeutics Institute, Inc.
104
JPY
+4
(+4.00%)
Apr 10, 3:30 pm JST
0.70
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
104.1
Apr 10, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.43
Yield
ー%
Margin Trading Ratio
899.63
Stock Price
Apr 10, 2025
Opening Apr 10, 9:00 am
105 JPY 0.71 USD
Previous Close Apr 9
100 JPY 0.68 USD
High Apr 10, 9:01 am
107 JPY 0.72 USD
Low Apr 10, 9:40 am
102 JPY 0.69 USD
Volume
793,300
Trading Value
0.08B JPY 0.56M USD
VWAP
104.08 JPY 0.71 USD
Minimum Trading Value
10,400 JPY 70 USD
Market Cap
4.71B JPY 0.03B USD
Number of Trades
437
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,014
1-Year High Feb 18, 2025
15,571
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 6,556,300
Mar 28, 2025 0 7,769,000
Mar 21, 2025 0 7,564,400
Mar 14, 2025 0 7,364,800
Mar 7, 2025 0 7,489,100
Company Profile
D.Western Therapeutics Institute, Inc. is a drug discovery venture originating from Mie University, focusing on protein kinase inhibitors and developing glaucoma treatments.
Sector
Pharmaceuticals
D.Western Therapeutics Institute, Inc. conducts research and development of pharmaceuticals in the ophthalmology field, primarily centered on protein kinase inhibitors, and operates a drug discovery business that licenses out its developed products to pharmaceutical companies. Their main product, ripasudil hydrochloride hydrate, has been launched in Japan and Asia as a treatment for glaucoma and ocular hypertension, and is also being developed for expanded use in Fuchs' endothelial corneal dystrophy. Additionally, the ophthalmic surgical aid DW-1002 is currently on sale in Europe and the United States, and is under development in Japan. Clinical trials for their in-house developed product H-1337 are also underway. The company has established an efficient research and development system by utilizing their proprietary Drug Western method and actively collaborating with universities and other companies.